Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company is developing targeted hyperthermia, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. It is engaged in the development of pre-clinical nanomedical therapy for the treatment of cancer using its proprietary and biocompatible gold nanorods (GNR) leveraging on its core manufacturing technology for these biocompatible GNRs, scientific experience, accumulated study data and laboratory. It has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.